Opaleye/James Silverman hold 8.59% of Q32 Bio (NASDAQ: QTTB)

Rhea-AI Filing Summary

Opaleye Management Inc., Opaleye, L.P. and James Silverman filed an amended Schedule 13G reporting shared beneficial ownership of 1,256,228 shares of Q32 Bio Inc. Common Stock, representing 8.59% of the class. The filing states the interest is based on 14,629,463 shares outstanding as of March 1, 2026, as reported in Q32 Bio's Form 10-K. The statement explains the Fund directly holds the shares, the Adviser serves as investment adviser, and Mr. Silverman controls the Adviser; the joint filing agreement is included.

Key Figures

Beneficially owned: 1,256,228 shares Percent of class: 8.59% Shares outstanding: 14,629,463 shares +2 more

5 metrics

Beneficially owned 1,256,228 shares Amount beneficially owned reported on Schedule 13G/A

Percent of class 8.59% Percent of Common Stock class reported in the filing

Shares outstanding 14,629,463 shares Outstanding as of March 1, 2026 (per Q32 Bio Form 10-K)

CUSIP 746964105 Identifier for Q32 Bio Common Stock

Filing signatures 05/06/2026 Signatures by James Silverman dated May 6, 2026

Key Terms

beneficially owned, shared dispositive power, Joint Filing Agreement, Schedule 13G/A

4 terms

beneficially owned regulatory

"Amount beneficially owned: 1,256,228.00"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

shared dispositive power regulatory

"Shared Dispositive Power 1,256,228.00"

Joint Filing Agreement regulatory

"Exhibit 99.1 Joint Filing Agreement by and among the reporting persons"

Schedule 13G/A regulatory

"(Amendment No. 1 ) Q32 Bio Inc. Common Stock"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Q32 Bio Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

746964105

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 746964105

1

Names of Reporting Persons

Opaleye Management Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MASSACHUSETTS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,256,228.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,256,228.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,256,228.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.59 %

12

Type of Reporting Person (See Instructions)

IA, CO

SCHEDULE 13G

CUSIP Number(s): 746964105

1

Names of Reporting Persons

Opaleye, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MASSACHUSETTS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,256,228.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,256,228.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,256,228.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.59 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: Based on 14,629,463 shares of Common Stock outstanding as of March 1, 2026, as reported by Q32 Bio Inc. in its Annual Report on Form 10-K filed with the SEC on March 10, 2026.

SCHEDULE 13G

CUSIP Number(s): 746964105

1

Names of Reporting Persons

James Silverman

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,256,228.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,256,228.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,256,228.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.59 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Q32 Bio Inc.
(b)	Address of issuer's principal executive offices: 830 Winter Street, Waltham, MA 02451
Item 2.
(a)	Name of person filing: Opaleye Management Inc. Opaleye, L.P. James Silverman This statement is filed by (i) Opaleye Management Inc. (the "Adviser"), (ii) Opaleye, L.P. (the "Fund") and (iii) James Silverman with respect to the shares of Common Stock, par value $0.0001 per share ("Common Stock"), of Q32 Bio Inc. (the "Issuer") directly held by the Fund. The Adviser serves as investment adviser to the Fund. Mr. Silverman exercises control over the Adviser. The filing of this statement should not be construed as an admission that any of the foregoing persons is, for the purposes of Section 13 of the Securities Exchange Act, the beneficial owner of the shares reported herein.
(b)	Address or principal business office or, if none, residence: One Boston Place, 26th Floor, Boston, MA 02108
(c)	Citizenship: Opaleye Management Inc. - Massachusetts Opaleye, L.P. - Massachusetts James Silverman - USA
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 746964105
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 1,256,228.00
(b)	Percent of class: 8.59 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 1,256,228.00
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 1,256,228.00
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Opaleye Management Inc.

Signature:	/s/ James Silverman
Name/Title:	President
Date:	05/06/2026

Opaleye, L.P.

Signature:	/s/ James Silverman
Name/Title:	General Partner
Date:	05/06/2026

James Silverman

Signature:	/s/ James Silverman
Name/Title:	Individually
Date:	05/06/2026

Exhibit Information

Exhibit 99.1 Joint Filing Agreement by and among the reporting persons

FAQ

What stake does Opaleye report in Q32 Bio (QTTB)?

Opaleye reports beneficial ownership of 1,256,228 shares (8.59%). The percentage is calculated using 14,629,463 shares outstanding as of March 1, 2026, per Q32 Bio's Form 10-K referenced in the filing.

Who are the reporting persons on the Schedule 13G/A for Q32 Bio?

The filing is by Opaleye Management Inc., Opaleye, L.P., and James Silverman. The Adviser manages the Fund, and Mr. Silverman is reported as exercising control over the Adviser.

Does the filing indicate sole voting or dispositive power for these holders?

The filing shows no sole voting or dispositive power. It reports 0 shares with sole power and 1,256,228 shares with shared voting and shared dispositive power.

What document confirms the joint reporting arrangement?

Exhibit 99.1 is a Joint Filing Agreement among the reporting persons. The filing includes signatures by James Silverman in his capacities as President, General Partner, and Individually dated 05/06/2026.

What CUSIP and class are reported for Q32 Bio in the filing?

CUSIP 746964105 and the class is Common Stock, par value $0.0001 per share. These identifiers are listed on the Schedule 13G/A cover information.